Technical Analysis for CRDL - Cardiol Therapeutics Inc.

Grade Last Price % Change Price Change
F 1.56 -5.45% -0.09
CRDL closed down 5.45 percent on Wednesday, November 20, 2024, on 1.11 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness -5.45%
Below Lower BB Weakness -5.45%
Down 3 Days in a Row Weakness -5.45%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 17 hours ago
Possible NR7 about 18 hours ago
2x Volume Pace about 22 hours ago
Down 5% about 22 hours ago
1.5x Volume Pace about 22 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cardiol Therapeutics Inc. Description

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Disease Clinical Research Heart Failure Orphan Drug Heart Disease Cannabidiol

Is CRDL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.12
52 Week Low 0.7925
Average Volume 520,172
200-Day Moving Average 1.96
50-Day Moving Average 1.97
20-Day Moving Average 1.86
10-Day Moving Average 1.85
Average True Range 0.14
RSI (14) 28.57
ADX 17.57
+DI 17.21
-DI 25.69
Chandelier Exit (Long, 3 ATRs) 1.83
Chandelier Exit (Short, 3 ATRs) 1.95
Upper Bollinger Bands 2.08
Lower Bollinger Band 1.64
Percent B (%b) -0.19
BandWidth 23.66
MACD Line -0.06
MACD Signal Line -0.03
MACD Histogram -0.0316
Fundamentals Value
Market Cap 101.58 Million
Num Shares 65.1 Million
EPS -0.32
Price-to-Earnings (P/E) Ratio -4.88
Price-to-Sales 1069.35
Price-to-Book 2.71
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.75
Resistance 3 (R3) 1.76 1.71 1.72
Resistance 2 (R2) 1.71 1.67 1.71 1.71
Resistance 1 (R1) 1.64 1.64 1.61 1.62 1.70
Pivot Point 1.59 1.59 1.58 1.58 1.59
Support 1 (S1) 1.51 1.54 1.49 1.50 1.42
Support 2 (S2) 1.46 1.51 1.46 1.41
Support 3 (S3) 1.39 1.46 1.40
Support 4 (S4) 1.37